JaxBio is transforming cancer diagnosis and management with a simple, highly sensitive blood test for early detection, disease monitoring, and treatment response prediction. Using a proprietary method, the company detects genetic and epigenetic profiles in cell-free DNA linked to cancer initiation and progression, offering major advantages over traditional diagnostics and liquid biopsies.
Its process fluorescently labels cell-free DNA markers, hybridizes them onto a custom chip, and uses AI to classify unique pixel-pattern signatures by cancer type and stage. JaxBio is currently developing diagnostic tests for lung cancer and hematological malignancies.
